CA2585642C - Carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof - Google Patents

Carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof Download PDF

Info

Publication number
CA2585642C
CA2585642C CA2585642A CA2585642A CA2585642C CA 2585642 C CA2585642 C CA 2585642C CA 2585642 A CA2585642 A CA 2585642A CA 2585642 A CA2585642 A CA 2585642A CA 2585642 C CA2585642 C CA 2585642C
Authority
CA
Canada
Prior art keywords
group
substituent groups
methoxy
substituent
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2585642A
Other languages
English (en)
French (fr)
Other versions
CA2585642A1 (en
Inventor
Masakazu Murata
Yoshihiko Itokazu
Ryu Nakao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Publication of CA2585642A1 publication Critical patent/CA2585642A1/en
Application granted granted Critical
Publication of CA2585642C publication Critical patent/CA2585642C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2585642A 2004-10-29 2005-10-28 Carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof Expired - Fee Related CA2585642C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-316872 2004-10-29
JP2004316872 2004-10-29
PCT/JP2005/020250 WO2006046779A1 (ja) 2004-10-29 2005-10-28 カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩

Publications (2)

Publication Number Publication Date
CA2585642A1 CA2585642A1 (en) 2006-05-04
CA2585642C true CA2585642C (en) 2013-04-02

Family

ID=36227999

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2585642A Expired - Fee Related CA2585642C (en) 2004-10-29 2005-10-28 Carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof

Country Status (16)

Country Link
US (1) US8329913B2 (enExample)
EP (1) EP1852433B1 (enExample)
JP (1) JP3997491B2 (enExample)
KR (1) KR101223820B1 (enExample)
CN (1) CN101048402B (enExample)
AT (1) ATE534646T1 (enExample)
AU (1) AU2005297800B2 (enExample)
CA (1) CA2585642C (enExample)
CY (1) CY1112649T1 (enExample)
DK (1) DK1852433T3 (enExample)
ES (1) ES2378177T3 (enExample)
PL (1) PL1852433T3 (enExample)
PT (1) PT1852433E (enExample)
SI (1) SI1852433T1 (enExample)
TW (1) TW200635922A (enExample)
WO (1) WO2006046779A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393181B2 (en) 2004-09-17 2008-07-01 The Penn State Research Foundation Expandable impeller pump
CN101448535B (zh) 2006-03-23 2011-10-19 宾州研究基金会 带有可膨胀叶轮泵的心脏辅助装置
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2448613B1 (en) 2009-07-01 2019-11-06 The Penn State Research Foundation Blood pump with expandable cannula
CN102666553B (zh) 2009-10-01 2015-05-06 赛马拜制药公司 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
CN102382037B (zh) * 2010-09-03 2016-01-20 中国医学科学院药物研究所 苯丙酸类化合物及其制法和药物用途
US8485961B2 (en) 2011-01-05 2013-07-16 Thoratec Corporation Impeller housing for percutaneous heart pump
US8597170B2 (en) 2011-01-05 2013-12-03 Thoratec Corporation Catheter pump
WO2012094641A2 (en) 2011-01-06 2012-07-12 Thoratec Corporation Percutaneous heart pump
WO2012094535A2 (en) 2011-01-06 2012-07-12 Thoratec Corporation Percutaneous heart pump
US9327067B2 (en) 2012-05-14 2016-05-03 Thoratec Corporation Impeller for catheter pump
GB2504177B (en) 2012-05-14 2014-12-10 Thoratec Corp Sheath system for catheter pump
GB2504176A (en) 2012-05-14 2014-01-22 Thoratec Corp Collapsible impeller for catheter pump
US9872947B2 (en) 2012-05-14 2018-01-23 Tc1 Llc Sheath system for catheter pump
US9446179B2 (en) 2012-05-14 2016-09-20 Thoratec Corporation Distal bearing support
US8721517B2 (en) 2012-05-14 2014-05-13 Thoratec Corporation Impeller for catheter pump
EP4186557A1 (en) 2012-07-03 2023-05-31 Tc1 Llc Motor assembly for catheter pump
US9421311B2 (en) 2012-07-03 2016-08-23 Thoratec Corporation Motor assembly for catheter pump
US9358329B2 (en) 2012-07-03 2016-06-07 Thoratec Corporation Catheter pump
US11033728B2 (en) 2013-03-13 2021-06-15 Tc1 Llc Fluid handling system
US11077294B2 (en) 2013-03-13 2021-08-03 Tc1 Llc Sheath assembly for catheter pump
WO2014164136A1 (en) 2013-03-13 2014-10-09 Thoratec Corporation Fluid handling system
US20160030649A1 (en) 2013-03-15 2016-02-04 Thoratec Corporation Catheter pump assembly including a stator
US9308302B2 (en) 2013-03-15 2016-04-12 Thoratec Corporation Catheter pump assembly including a stator
EP4417244A3 (en) 2014-04-15 2024-10-16 Tc1 Llc Catheter pump introducer system
US10583232B2 (en) 2014-04-15 2020-03-10 Tc1 Llc Catheter pump with off-set motor position
US10363349B2 (en) 2014-04-15 2019-07-30 Tc1 Llp Heart pump providing adjustable outflow
EP3131599B1 (en) 2014-04-15 2019-02-20 Tc1 Llc Catheter pump with access ports
US10029037B2 (en) 2014-04-15 2018-07-24 Tc1 Llc Sensors for catheter pumps
US10449279B2 (en) 2014-08-18 2019-10-22 Tc1 Llc Guide features for percutaneous catheter pump
WO2016118784A1 (en) 2015-01-22 2016-07-28 Thoratec Corporation Attachment mechanisms for motor of catheter pump
EP3247420B1 (en) 2015-01-22 2019-10-02 Tc1 Llc Reduced rotational mass motor assembly for catheter pump
EP3598986B1 (en) 2015-01-22 2021-02-17 Tc1 Llc Motor assembly with heat exchanger for catheter pump
US9907890B2 (en) 2015-04-16 2018-03-06 Tc1 Llc Catheter pump with positioning brace
EP3804804A1 (en) 2016-07-21 2021-04-14 Tc1 Llc Fluid seals for catheter pump motor assembly
EP3808401A1 (en) 2016-07-21 2021-04-21 Tc1 Llc Gas-filled chamber for catheter pump motor assembly
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
CA3077273A1 (en) 2017-10-06 2019-04-11 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
US12522850B2 (en) 2019-12-19 2026-01-13 Abiochem Biotechnology (Group) Co., Ltd. Fluoroacetate dehalogenase mutant and application thereof
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003377A1 (en) 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
CN1233176A (zh) 1996-10-30 1999-10-27 伊莱利利公司 取代的三环化合物
MY125942A (en) * 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
WO2001026653A1 (en) 1999-10-15 2001-04-19 Shionogi & Co., Ltd. V TYPE AND/OR X TYPE sPLA2 INHIBITORS
WO2002000255A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
WO2002000256A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000257A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
TWI314457B (enExample) 2001-03-19 2009-09-11 Shionogi & Co
ATE353876T1 (de) 2001-03-28 2007-03-15 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
WO2004024939A2 (en) * 2002-09-13 2004-03-25 Georgetown University Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity

Also Published As

Publication number Publication date
CN101048402A (zh) 2007-10-03
KR101223820B1 (ko) 2013-01-17
KR20070072554A (ko) 2007-07-04
CN101048402B (zh) 2011-11-09
TW200635922A (en) 2006-10-16
ATE534646T1 (de) 2011-12-15
US20100286210A1 (en) 2010-11-11
ES2378177T3 (es) 2012-04-09
EP1852433B1 (en) 2011-11-23
US8329913B2 (en) 2012-12-11
AU2005297800A1 (en) 2006-05-04
DK1852433T3 (da) 2012-01-30
AU2005297800B2 (en) 2011-02-03
CY1112649T1 (el) 2016-02-10
PL1852433T3 (pl) 2012-05-31
WO2006046779A1 (ja) 2006-05-04
SI1852433T1 (sl) 2012-06-29
CA2585642A1 (en) 2006-05-04
TWI359148B (enExample) 2012-03-01
EP1852433A1 (en) 2007-11-07
JP3997491B2 (ja) 2007-10-24
JPWO2006046779A1 (ja) 2008-05-22
PT1852433E (pt) 2012-02-08
EP1852433A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
CA2585642C (en) Carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof
JP5290749B2 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
JP5580201B2 (ja) グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用
US6147099A (en) Oxazolidinedione derivatives, their production and use
JP4276074B2 (ja) ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2002053547A1 (en) Alkanoic acid derivatives, process for their production and use thereof
US6011036A (en) Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
WO1996038428A1 (en) N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
KR20080040046A (ko) 티아졸 유도체
WO2008016175A1 (en) Activator for peroxisome proliferator activated receptor
US5591862A (en) Tetrazole derivatives, their production and use
US20030073862A1 (en) Compounds
US5889032A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
KR101118574B1 (ko) 당뇨병 및 지질 질환 치료용 크로만 카르복시 산 유도체
JP3466273B2 (ja) テトラゾール誘導体、その製造法およびそれを含んでなる医薬
WO2006117743A1 (en) Substituted aromatic compounds as antidiabetic agents
JP3836521B2 (ja) ２，４−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
WO2005095364A1 (ja) フェノキシ酢酸誘導体及びそれを用いた医薬
WO2005058813A2 (en) Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents
JPH09176163A (ja) ２，４−チアゾリジンジオン又はオキサゾリジンジオン誘導体と血糖降下剤
HK1135377B (en) ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181029